- Home
- SWZ vs BSEM Comparison
SWZ vs BSEM Comparison
Compare SWZ & BSEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SWZ | BSEM |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.3M | 76.9M |
| IPO Year | N/A | 2026 |
Fundamental Metrics
Financial Performance| Metric | SWZ | BSEM |
|---|---|---|
| Price | $5.85 | $4.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.8K | ★ 127.7K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.83 | $2.25 |
| 52 Week High | $6.31 | $5.44 |
Technical Indicators
Market Signals| Indicator | SWZ | BSEM |
|---|---|---|
| Relative Strength Index (RSI) | 27.84 | 49.09 |
| Support Level | N/A | $3.66 |
| Resistance Level | $6.00 | $4.02 |
| Average True Range (ATR) | 0.04 | 0.47 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 5.26 | 14.29 |
Price Performance
Historical ComparisonAbout SWZ Swiss Helvetia Fund Inc. (The)
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. It actively manages investment solutions spanning public and private markets, wealth management, and Solutions.
About BSEM BioStem Technologies Inc. Common Stock
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.